Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Licenses miRNA Analysis Technology from Rosetta Inpharmatics

NEW YORK (GenomeWeb News) – Exiqon said today that it has licensed microRNA analysis technology from Merck subsidiary Rosetta Inpharmatics. 
 
The license covers real-time PCR technology used in quantitative miRNA analysis. The technology was developed for microRNA biomarker analysis at Merck.
 
Exiqon said it will use the technology in a product line for detecting miRNA that it plans to release later this year.
 
Financial terms of the agreement were not released.
 
“Being able to market quantitative real-time PCR products for miRNA analysis complements the current product offerings based on microarrays, in situ detection and knockdown products for miRNA research and expands Exiqon’s offerings for microRNA biomarker analysis,” said Exiqon CEO Lars Kongsbak.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.